Record quarterly revenue and double-digit adjusted EBITDA growth were driven by strong industrial and consumer segments, margin expansion, and ongoing restructuring benefits. Guidance for 2026 is reaffirmed, with continued investment in lab capacity and portfolio optimization.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.